{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:54:02Z","timestamp":1761630842630},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.medcli.2018.08.002","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T08:30:09Z","timestamp":1538728209000},"page":"377-383","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["An\u00e1lisis de los \u00edndices predictores de respuesta al tratamiento con \u00e1cido ursodeoxic\u00f3lico en pacientes con colangitis biliar primaria"],"prefix":"10.1016","volume":"152","author":[{"given":"Eduard","family":"Brunet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Miquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"S\u00e1nchez-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blai","family":"Dalmau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meritxell","family":"Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2018.08.002_bib0155","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.cgh.2015.08.025","article-title":"Changing nomenclature for PBC: From\u2019cirrhosis\u2019 to\u2019cholangitis\u2019","volume":"13","author":"Beuers","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2018.08.002_bib0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4292\/wjgpt.v6.i3.32","article-title":"Primary biliary cirrhosis: From bench to bedside","volume":"6","author":"Kouroumalis","year":"2015","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"10.1016\/j.medcli.2018.08.002_bib0165","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.medcli.2018.08.002_bib0170","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology."},{"key":"10.1016\/j.medcli.2018.08.002_bib0175","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology."},{"key":"10.1016\/j.medcli.2018.08.002_bib0180","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrosis: Biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2018.08.002_bib0185","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.medcli.2018.08.002_bib0190","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology."},{"key":"10.1016\/j.medcli.2018.08.002_bib0195","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1038\/ctg.2017.23","article-title":"Prognostic factors for transplant-free survival and validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid","volume":"8","author":"Cheung","year":"2017","journal-title":"Clin Transl Gastroenterol."},{"key":"10.1016\/j.medcli.2018.08.002_bib0200","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2018.08.002_bib0205","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2018.08.002_bib0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.medcli.2018.08.002_bib0215","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2018.08.002_bib0220","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology."},{"key":"10.1016\/j.medcli.2018.08.002_bib0225","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol."},{"key":"10.1016\/j.medcli.2018.08.002_bib0230","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/apt.13448","article-title":"Population-based epidemiology of primary biliary cirrhosis in South Korea","volume":"43","author":"Kim","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.medcli.2018.08.002_bib0235","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"1","author":"Gluud","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2018.08.002_bib0240","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2036.2005.02318.x","article-title":"Long-term ursodeoxycholic acid therapy for primary biliay cirrosis: A follow-up to 12 years","volume":"21","author":"Chan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2018.08.002_bib0245","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2018.08.002_bib0250","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: Risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medcli.2018.08.002_bib0255","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycolic acid and long-term prognosis of primary biliary cirrosis: Results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2018.08.002_bib0260","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestasic effects of bezafibrate in patients with primary biliary cirrosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2018.08.002_bib0265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.medcli.2018.08.002_bib0270","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/qjmed\/hch078","article-title":"Patterns of autoimmunity in primary biliary cirrhosis patients and their families: A population-based cohort study","volume":"97","author":"Watt","year":"2004","journal-title":"QJM."},{"key":"10.1016\/j.medcli.2018.08.002_bib0275","doi-asserted-by":"crossref","first-page":"11335","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis","volume":"43","author":"Wesierska-Gadek","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2018.08.002_bib0280","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/jgh.13746","article-title":"Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis","volume":"32","author":"Seki","year":"2017","journal-title":"J Gastroenteol Hepatol."},{"key":"10.1016\/j.medcli.2018.08.002_bib0285","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.medcli.2015.02.026","article-title":"Implicaci\u00f3n pron\u00f3stica de las manifestaciones cl\u00ednicas extrahep\u00e1ticas, autoinmunidad y capilaroscopia ungueal microsc\u00f3pica en pacientes con cirrosis biliar primaria","volume":"146","author":"Mar\u00ed-Alfonso","year":"2016","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2018.08.002_bib0290","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2018.08.002_bib0295","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.4254\/wjh.v8.i33.1419","article-title":"Recent advances in the diagnosis and treatment of primary biliary cholangitis","volume":"8","author":"Huang","year":"2016","journal-title":"World J Hepatol."},{"key":"10.1016\/j.medcli.2018.08.002_bib0300","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318305098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318305098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T16:15:11Z","timestamp":1556381711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775318305098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0025775318305098"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2018.08.002","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An\u00e1lisis de los \u00edndices predictores de respuesta al tratamiento con \u00e1cido ursodeoxic\u00f3lico en pacientes con colangitis biliar primaria","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2018.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}